Intranasal Insulin for Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Systematic Review and Meta-analysis
![]() |
Alnajjar, Sarah
(Division of Life and Pharmaceutical Sciences Graduate School, Ewha Womans University)
Jin, Hye Kyung (College of Pharmacy, Ewha Womans University) Kang, Ji Eun (Division of Life and Pharmaceutical Sciences Graduate School, Ewha Womans University) Park, So Hyun (Division of Life and Pharmaceutical Sciences Graduate School, Ewha Womans University) Rhie, Sandy Jeong (Division of Life and Pharmaceutical Sciences Graduate School, Ewha Womans University) |
1 | Steen E, Terry BM, Rivera EJ, et al. Wands and S. M. de la Monte. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005;7(1):63-80. DOI |
2 | de la Monte SM and Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008;2(6):1101-13. DOI |
3 | Kroner Z. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev 2009;14(4):373-9. |
4 | Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011;71(3):365-76. DOI |
5 | Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2006;366(9503):2112-7. DOI |
6 | Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6. DOI |
7 | Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: Localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991;36(5):343-62. DOI |
8 | Plum L, Schubert M, Bruning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 2005;16(2):59-65. DOI |
9 | Xie L, Helmerhorst E, Plewright B, et al. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002;22(10):1-5. |
10 | McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease Report of the NINCDS?ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44. DOI |
11 | Claxton A, Watson GS, Baker L. Craft. Gender differences in cognitive benefits of intranasal insulin. Alzheimers Dement 2011;7(4):S778-9. |
12 |
RReger MA, Watson G, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid- |
13 |
Reger M, Watson G, Green P, et al. Intranasal insulin improves cognition and modulates |
14 | Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38. DOI |
15 | Hanson LR and Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9(Suppl 3):S5. |
16 | Kiecolt-Glaser JK, Glaser R, Shuttleworth EC, et al. Chronic stress and immunity in family caregivers of Alzheimer's disease victims. Psychosom Med 1987;49(5):523-35. DOI |
17 |
Kulstad J, Green P, Cook D, et al. Differential modulation of plasma |
18 | Woods SC, Seeley RJ, Baskin DG, et al. Insulin and the blood-brain barrier. Curr Pharm Des 2003;9(10):795-800. DOI |
19 | Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. DOI |
20 | Duval S and Tweedie R. Trim and fill: a simple funnel?plot-based method of testing and adjusting for publication bias in meta?analysis. Biometrics 2000;56(2):455-63. DOI |
21 | Nicolls MR. The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res 2004;1(1): 47-54. DOI |
22 | Claxton A, Baker LD, Wilkinson CW, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimers Dis 2013;35(4):789-97. DOI |
23 | Rosenbloom MH, Barclay TR, Pyle M, et al. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS drugs 2014;28(12): 1185-9. DOI |
24 | Claxton A, Baker LD, Hanson A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 2015;44(3):897-906. DOI |
25 | Higgins J and Thompson SG. Quantifying heterogeneity in a meta?analysis. Stat Med 2002;21(11):1539-58. DOI |
26 | Reger M, Watson G, Frey WN, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27(3):451-8. DOI |
27 | Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009;110(4):1129-34. DOI |
28 | Convit A. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 2005;26(1):31-5. DOI |
29 | Watson GS and Craft S. The Role of Insulin Resistance in the Pathogenesis of Alzheimer's Disease. CNS Drugs 2004;17(1):27-45. DOI |
30 | Craft S. Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005;26(Suppl 1):65-9. DOI |
![]() |